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Abstract
New vehicles for the non-invasive delivery of agents are introduced. These carriers can transport pharmacological agents,
including large polypeptides, through the permeability barriers, such as the intact skin. This capability depends on the
self-regulating carrier deformability which exceeds that of the related but not optimized lipid aggregates by several orders of
magnitude. Conventional lipid suspensions, such as standard liposomes or mixed lipid micelles, do not mediate a systemic
biological effect upon epicutaneous applications. In contrast to this, the properly devised adaptable carriers, when
administered on the intact skin, transport therapeutic amounts of biogenic molecules into the body. This process can be
nearly as efficient as an injection needle, as seen from the results of experiments in mice and humans with the
insulin-carrying vesicles. The carrier-mediated transcutaneous insulin delivery is unlikely to involve shunts, lesions or other
types of skin damage. Rather than this, insulin is inferred to be transported into the body between the intact skin cells with a
bio-efficiency of at least 50% of the s.c. dose action. q 1998 Elsevier Science B.V.
Keywords: Transfersome; Vesicle; Insulin
1. Introduction
Large biogenic or biotechnologic molecules are
normally delivered into the body by means of an
injection needle. However, numerous and ingenious
w xattempts were made to improve on this 1,2 . They
were based on inventive galenic formulations, includ-
w x w xing oral polymer 3 , liposome 4 or microemulsion
w x5,6 suspensions, on the technical innovations, such
w x w xas subcutaneous reservoirs 7 and pumps 8 , or on
w x w xthe unusual, e.g. rectal 9 , periocular 10 , intranasal
) Corresponding author. Fax: q49 89 4140 4980.
w x w x11 or dermal 6 applications. None of these ap-
proaches to date gave completely satisfactory results.
The reasons for this are manifold. Orally applied
polypeptidic or proteinaceous drugs are digested in
the gastro-intestinal tract, by and large, and thus are
therapeutically nearly inactive. Macromolecules
placed in the nose or on the intact skin face the
natural permeability barrier optimized by the evolu-
tion to keep the foreign substances out of the body;
very few, if any, large entities therefore cross the
intercellular passages in such barrier. What is the
basic cause of this?
Pushing a large molecule or a particle through the
0005-2736r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved.
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pore with diameter much smaller than the ‘permeant’
size is extremely energy-demanding, if not impossi-
ble; the molecular or particle segregation in the renal
or sterile filtration, based on such size exclusion
exemplifies this.
By using the concept of rational membrane design
w x12 we have recently devised special composite bod-
1 w xies, so-called Transfersomes 13 , which overcome
the filtration problem: Transfersomes are sufficiently
flexible to pass even through the pores appreciably
smaller than their own size. By optimally matching
the penetrant adaptability to the transport-induced
stress the size-exclusion principle is evaded nearly
completely. The resulting highly deformable vesicles
then pass through the narrow, otherwise confining,
pores with the efficacy of water, 1000 times smaller.
This article provides some evidence for this and
also elucidates the mechanism of lipid aggregate
penetration through various barriers in terms of vesi-
cle local composition and shape adjustments. Our
report, moreover, illustrates the use of highly de-
formable vesicles for the spontaneous transcutaneous
delivery of drugs and discusses the practical value of
such an approach.
2. Experimental
2.1. Permeation across an artificial barrier
Permeation across an artificial barrier was deter-
mined in a dedicated, home-built device. In short, the
flux of vesicle suspension through a large number of
pores of known size e.g. through a sandwich of
different micro-porous filters with the pore diameter
between 50 and 400 nm, depending on the starting
.transfersome suspension was driven by an external
 .pressure originally 3 MPa, later typically G0.5 MPa
and measured as a function of time. The relative
permeation capability of the investigated suspension
was then calculated by using standard hydrostatic-
flow expression P s jrD p, the result of calcu-Transf
lation being calibrated relative to the corresponding
value measured with the pure water Permeations
1 Transfersomese: from the Latin ‘transferre’, to carry, and
Greek ‘soma’, body.
.P rP =100% . The dynamic light scatteringTransf water
and HPLC were used before and after each experi-
ment to control the degree of filtration and the changes
in particle size.
2.2. Vesicle size determinations
The dynamic light scattering measurements were
done in triplicate with a Zetasizer 2C instrument
 .Malvern Instruments, Malvern, UK . They were ana-
lyzed by the multi-tau procedure from an Autosizer
software package.
2.3. Liposomes preparation
Liposomes consisting of soybean phosphatidyl-
 .choline SPC were prepared by the standard method.
In brief, an organic solution of the required lipid
 .mixture was first dried under vacuum 10 Pa
overnight. The resulting lipid film was then hydrated
 .with triethanolamine–HCl buffer pHs6.5 to pre-
pare a 10% lipid suspension. This suspension was
sonicated for 60 min at 48C until the desired vesicle
radius was achieved. The latter was measured by the
dynamic light scattering.
2.4. Transfersomes preparation
In short, transfersomes were prepared by mixing
an ethanolic SPC solution with the appropriate amount
of an edge-active molecule, such as sodium cholate.
One kind of resulting charged suspension contained
8.7 wt% SPC and 1.3 wt% cholate as well as approx.
8.5 vol% ethanol, unless stated otherwise. Other bio-
compatible surfactants were used in different suspen-
w xsions 38 . The suspension was subsequently mixed
with triethanolamine–HCl buffer to yield total lipid
concentration of 10 wt%. The resulting suspension
 .was sonicated, frozen, and thawed 2–3 times and
brought to the desired size as measured by means of
.photon correlation spectroscopy by ultrasonication
or intermediate-pressure homogenization. Vesicle
suspension was ultimately sterilized by filtration
through a 0.2 mm micro-porous filter Poretics, CA,
.USA . The final vesicle size was confirmed by the
dynamic light scattering.
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2.5. Transfersulin preparation
Transfersulin preparation was based on a common
pharmaceutical formulation of human recombinant
insulin HRI: Actrapid 100 or 45 HM; Boehringer-
.Novo, Mannheim, Germany . The starting insulin
solution thus contained approximately 4 or 2 mg of
 .polypeptide, and 3 mg 1.5 mg m-cresol per ml. To
prepare 1 ml of Transfersulin, 0.84 ml of the original
solution was mixed, for example, with 88 mg of SPC
and approx. 12 mg sodium cholate or an appropriate
 . amount of other detergent p.a. in 0.1 ml ethanol. In
experiments with Actrapid 45 HM, the total lipid
concentration was halved and the cholate concentra-
.tion was increased by 10 mol%. The resulting crude
suspension was homogenized to yield a mixture of
vesicles with a radius of approximately 90–110 nm.
These transfersomes were then sterilized by filtration
through a 0.22 mm pore filter Sartorius, Gottingen,¨
.Germany and used for experiments within the next
24 h. The final concentration of insulin in all transfer-
somal preparations was nominally 84"2 Urml or
40 Urml. Other transfersome compositions are de-
w xscribed in detail in Ref. 38 .
2.6. Skin penetration and bio-efficacy tests in ˝i˝o
The total amount of the drug- or carrier-derived
radioactivity in the body provided information on the
skin penetration capability. For this purpose, phos-
phatidylcholine tritinurated in choline group and iodi-
nated insulin were used. The former was incorporated
quantitatively into lipid aggregates. The radioactive
insulin was associated with carriers to ;90%. The
concentration of these labels was measured in mice
w xas described in our previous publications 37 . In
brief, all blood and tissue samples were discolored
with 0.4 ml H O and 0.2 ml HClO at 808C2 2 4
overnight. Subsequently, the samples were neutral-
ized with 0.2 ml CH COOH and 10 ml of Aquasol-23
 .NEN-DuPont, Dreieich, FRG was added. The total
radioactivity was determined with a b-scintillation
 .counter Canberra-Packard, Dreieich, Germany or
 .with a g-counter Berthold, Wildbad, Germany .
The values assigned to the skin ‘Surface’ represent
the sum of all counts from the stratum corneum
strippings. Carcass means the residual body with the
exception of the individually represented organs or
tissues.
The whole body pictures were determined in the
laboratories of Merck AG, by the courtesy of Dr.
Steiner.
Transfersulin always contained the rapidly acting
human recombinant insulin Actrapid HM;
.Boehringer-Novo, Mannheim at the given concentra-
tion. Blood glucose concentration was normally mea-
sured with a standard glucose-dehydrogenase blood
 .glucose assay Merck, Gluc-DH in triplicate.
2.6.1. Murine experiments
Each experimental group consisted of 4–8 female
 .NMRI mice 32 g, 8–12 weeks old with manually
trimmed hair. Mice were kept in individual cages and
typically had the blood glucose concentration of
120 mgrdl after the fasting period of 6 h. This start-
ing glucose level was determined by averaging the
results of three separate values measured between
tsy2 h and tF0 h, but the day-to-day variability
 .was up to 20%. At ts0, Transfersulin v , insulin
 .associated with ethanolic 10% phosphatidylcholine
 .  .PC liposomes ‘ or with phosphatidylcholinerbile
 .salt PCrBS, 65r35 rel. wt%, 7% ethanol mixed
 .micelles e was applied on the test animals back
 .0.45 Urmouse non-occlusively. 20 ml blood sam-
ples were collected from the tail end. The correspond-
 .ing average mean: y blood glucose concentration
always represents the net insulin-induced hypo-
glycemia. Its value was calculated as follows. First,
the corresponding average result measured with the
untreated or empty-transfersome treated animals,
 .y negative controls, = , was subtracted fromcontrol
 .each individual glucose concentration value: y t s
 . y t yy . The drift in the original data setuncor control
for the latter two groups was essentially absent for
tF4 h but increased quasi-linearly to F20% during
.  .the following 12 h. Second, the average value, y 0 ,
of all data points measured at tF0 was calculated
typically 3 per mouse, only 2 of which are shown in
.Fig. 4 . Third, the relative concentration change was
  .  . .determined as: y t ry 0 y1 =100%.
Owing to the difficulty of hypoglycemia-experi-
ments in mice the standard deviation of all experi-
mental points was rather large; the extra uncertainty
caused by the non-invasive use of Transfersulin only
added the factor of 1.5 to this uncertainty.
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2.6.2. Human experiments
 .After an initial test period G40 min , insulin
preparations were uniformly smeared over the intact
skin surface on the inner side of one forearm of
healthy volunteers 60–80 kg, age 30–40, starting
blood glucose levels between 73 and 85 mgrdl, fast-
.ing for 20"2 h . 45 U of Transfersulin were typi-
cally used on an area 45–90 cm2. In the early experi-
ments, in which also the C-peptide was measured,
 .blood samples 2–4 ml were drawn every 10–30 min
through a soft intravenous catheter placed in the other
arm. In some experiments the catheter was flushed
 .with 0.25 ml of heparin 2500 U every 2–3 h without
an observable effect on the experimental results. The
 .first 0.25 ml of each sample after heparin use 1 ml
were routinely discarded. Three independent samples
were measured at least in triplicate, resulting in SDF
3 mgrdl. In the latter experiments, which make out
20% of the represented data, the blood samples were
drawn from a finger tip. They were processed by
 .standard method mentioned above in triplicate .
The epicutaneously used ethanol-containing lipo-
  . .somes 10%; PCrPG 9r1 MrM , 10% EtOH or
 .PCrBS mixed micelles 65r35 rel. wt% with in-
 .sulin and EtOH 7% gave data represented by ‘
and e the corresponding 3-point average curves as
– – and , respectively.
2.7. Insulin and C-peptide in the serum
The basal insulin level in normoglycemic humans
is 2–20 Urml; the basal level of C-peptide, a co-
product of insulin secretion by the pancreas, is 0.2–
2.5 ngrml. This means that the serum C-peptide con-
centration normally exceeds that of insulin by the
factor of 5, owing to different elimination times. Any
significant deviation from the above mentioned value
is indicative of the systemic delivery of exogenous
insulin, for example, by means of Transfersomes. We
therefore checked the change in the molar
insulinrC-peptide ratio after epicutaneous Transfer-
sulin administrations by radioimmunoassays. The
used test kits were applicable in the range 1.5–
 .500 mUrml for insulin Isotopen Diagnostics; CIS
and 0.1–20 ngrml for C-peptide Byk-Sangtic Diag-
.nostics ; all measurements were done in the en-
docrinological laboratory of the 3rd Medical Clinic,
TU Munich, by courtesy of Prof. P. Botterman.
To facilitate the resulting data comparison, the
average starting insulin concentrations for each indi-
vidual experiment were normalized to the value of
6 mUrml, that gives the average starting value of all
experiments. Similarly, the starting C-peptide levels
were normalized to 1 ngrml. Insulin values G
 .25mUrml 4% of the total data were not considered,
as it is believed that such high values some in the
.range 100–500 mUrml were due to the sample con-
tamination with the insulin from the skin.
2.8. The statistical significance
The statistical significance in the time-dependence
curves of blood glucose was evaluated by assuming a
Gaussian distribution for the blocks of data typically
consisting of 20 individual values and then determin-
ing the 95% confidence limit.
To test the significance of the change in the serum
insulin concentration the following procedure was
used. Each insulinrC-peptide data-pair was first con-
verted into the molar ratio. Subsequently, the change
of the latter relative to the average starting value was
individually calculated. This gave 230 data points
which were combined and sorted according to time.
30 consecutive values were grouped and analysed
assuming Gaussian distribution. This provided infor-
mation on the variability of the average insulinrC-
peptide ratio in the serum at each given time and the
corresponding 90% confidence interval.
In other cases, Students t-test procedure from the
 .graphical package ORIGIN MicroCal, Amherst, MA
was used.
3. Results
In the following, our chief findings are presented
in a logical sequence stressing the key issues.
Transepidermal water activity gradient can
push the hydrophilic entities into and across the
skin if their resistance to penetration is small
enough. We have previously provided rather direct
evidence for this claim, based on the results of animal
w xstudies 13 . More recently, computer simulations
w xwere done 15 and compared with the measured data
G. Cevc, G. Gompper, D. Kroll, D. Gebauer, to be
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.published , suggesting the following picture of spon-
taneous vesicle motion through a narrow pore.
A small driving pressure that acts on a soft vesicle
or, by inference, a much higher stress acting on a
.less flexible membrane deforms the vesicle only
w xlittle 15 . Vesicle consequently does not protrude
deep into the pore and attains a locally stable confor-
mation. Conversely, the vesicle that gets into a pore
to a distance comparable to the pore radius profits
appreciably from the lower potential energy that is,
.from the higher water activity inside the pore. Such
vesicle then tends to be sucked into the pore sponta-
neously. When this happens, for example due to a
spontaneous thermal fluctuation at the pore entrance,
the permeability value becomes proportional to the
driving force and permits relatively rapid vesicle
w xmotion across the pore 15 .
Vesicle motion can be driven by an applied force
but for the polar aggregates mainly the transdermal
osmotic force, F , is important when the suspen-trans
sion is administered non-occlusively. If so, the force
magnitude is roughly proportional to the number of
the osmotically sensitive molecules in each carrier:
F An . Small aggregates, such as mixed mi-trans aggreg
celles, are thence less sensitive to the naturally occur-
ring transepidermal hydration gradient than the larger
bodies. The problem with the latter is, however, that
they are normally excluded more efficiently from the
pore.
Overcoming the size exclusion principle de-
pends on the controlled lowering of the energetic
cost for penetrant deformation. This can be real-
ized by combining into a single entity two or more
components with sufficiently different packing char-
acteristics and ‘spontaneous curvature’. This permits
the resulting blend to change its composition tran-
siently at the sites of large, and typically non-uni-
form, stress: the component which sustains the defor-
mation better is accumulated while the less adaptable
bilayer component is diluted at the maximally stressed
site. Properly made and designed, composite ultrade-
formable bodies are therefore self-optimizing: their
components flow between the sites of different defor-
mation which ensures the high transfersome deforma-
bility. A direct consequence of this is the optimum
pore-penetration capability of judiciously prepared
mixed lipid vesicles.
To formalize this idea one can argue as follows.
When the vesicle of radius r is pushed into av
confining pore with the radius r Fr work mustpore v
be done to pay for the activation energy of the
process, Ga. This energy, in the simplest approxima-
tion, is proportional to the relative surface area of
 .2 w xeach vesicle, r rr 13 and to the membranepore v
elastic energy: Ga ’GasDG . This elasticpenetration elast
energy, in the simplest approximation, is given by the
standard expression for the vesicle membrane de-
w xformability: G skr2 16 and is roughly propor-elast
 .tional to the square of the relative vesicle radius.
Anomalous membrane deformability can be
modelled in terms of the stress-dependent rigidity
˜ .factor, d c , which scales the elastic membrane en-
˜ . w xergy, G sd c kr2 17 , relative to the elasticelast
energy of a standard membrane G skr2.elaststandard.
˜ .When the value of d c is low the energetic cost of
elastic membrane deformation is also small. Mem-
branes of low rigidity thus become extremely flexible
under certain stress conditions. The resulting mem-
brane-confined bodies, consequently, are strongly de-
formable in a stress-dependent manner.
To determine the relevance of aggregate adaptabil-
ity in the process of the enforced permeation one can
consider the logarithm of permeability value, which
is inversely proportional to the corresponding activa-
tion energy:
log PAexp yGarRT . 1 . .
Fig. 1. The effect of relative particle size on the effective
 .trans-barrier permeation of transfersome 2 wt% total lipid; or
 .liposome 2% PC; suspensions driven by an external pressure, D
p. Inset: The average transfersome size after passage through the
pores.
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When this activation energy is sufficiently smaller
than the thermal energy, GarRT<1, the above
expression may be linearized
21 rpore
PA 2 . /
˜ rdk v
 .to correlate the effective dynamic elasticity and
˜ .deformability value, G or d c k with the mea-elast
sured permeability in the systems with a known
 .2  .  .relative size ratio, r rr . Eqs. 1 and 2 , more-pore v
over, permit the calculation of the average pore size
˜from the P-value if dk is known.
The elastic energy of liposomes is much higher
w xthan the thermal energy, 15RTFk;20RT 16,18 .
Conventional vesicles are therefore too stiff to pene-
trate through the pores smaller than approximately 2
 .vesicle diameters cf. Fig. 1, ‘ . Liposomes, conse-
quently, do not cross the intact skin or get into the
 .body cf. Fig. 2, right . In contrast to this, Transfer-
somes, characterized by the high and nearly size-in-
 . dependent cf. Fig. 1, v but stress-affected cf. Fig.
.2, v P-value, can pass through the skin barrier
 .nearly quantitatively cf. Fig. 2, right panel .
By analyzing the data given in Fig. 1 by means of
 .  .Eqs. 1 and 2 we infer that the observed transport
capability difference is mainly due to the lower elas-
ticity of liposomal in comparison with the transferso-
mal membranes. From the membrane surface fluctua-
 .tions analysis Gebauer and Cevc, to be published
˜we estimate that for transfersomes the average dk
value is F1–3RT. The existence of the temperature
induced, short-ranged surface fluctuations on the sur-
face of typical Transfersomes, seen in the inset to
Fig. 2, confirms the smallness of k .transf
The dynamic rigidity factor of transfersomes can
be deduced from the stress-dependent permeability
 .  .  .Fig. 2. Left: The relative permeability of the mixed lipid micelles e , transfersomes v or liposomes ‘ as a function of the
 .flow-driving pressure difference across the artificial barrier r s200 nm . All suspensions contained 2% total lipid and hadpore
compositions described in the text. The permeability values are given in % of the average value measured with water. Inset: A high
 . magnification freeze-fracture electron micrograph of a large r s300 nm , thermally undulated transfersome with k sRT. Picturev transf
.by courtesy of E. Sackmann and I. Sprenger, both TU Munich. Right: the absolute efficacy of phospholipid transfer across the intact
murine skin, as determined with the tritiurated dipalmitoylphosphatidylcholine, when this substance is incorporateed into mixed micelles
 .  .  .gray , liposomes white or transfersomes black .
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data as given in Fig. 2. To this end, the data mea-
sured with liposomes in the range of low permeation
˜
defdriving pressures are first used to fix d s1 for
w xk ,20RT 18 . From the results obtained withlipos
transfersomes, for which one has k “1, thetransf
rigidity factor for the optimized, composite vesicles is
˜then estimated to be very small: d;0.07. This value
is sensitive to the penetration-driving pressure in the
˜ ˜ .case of transfersomes, d sd D p <1, but nottransf
for liposomes.
Transition between the moderate and high perme-
 .ation or deformation regimen occurs near d ps1.5
5  .=10 pa, when transfersomes 2% total weight
 .consist of phosphatidylcholine PC, 1.695 wt% and
 .bile salt BS, 0.305 wt% . In the low pressure region
one gets for such typical suspension: k ,2–5RTtransf
125  .Fig. 3. Bio-distribution of the I-insulin derived radioactivity in rats after an epicutaneous administration on dorsum upper panel or an
 .  .injection under the dorsal skin lowest panel . The middle panel gives the insulin-derived radioactivity distribution in mice ns4 8 h
after the epicutaneous administration of radio-labelled drug in Transfersomes. Owing to the lag-time of the transcutaneous insulin delivery
the drug bio-distributions after e.c. and s.c. administration is not identical. Data likeness is sufficient, however, to prove that the
ultradeformable carriers transport their associated drug into the body similar to the subcutaneous injection. Auto-radiographic pictures
were done by the courtesy of Dr. Steiner from Merck AG; the upper one is blurred at the skin surface owing to the radio-label diffusion in
the embedding matrix. For further details see the text.
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˜and d;0.1 whilst above d ps0.5 mpa one has:
y3 y3
˜
y5 .1;k F10 RT and 5=10 Fd D p F10 .transf
˜The upper limit estimate for d stems from Fig. 1.
The high trans-barrier flow of transfersomes is
due to the maximum stress-induced vesicle de-
formability rather than to the stress-induced vesicle
fragmentation. This conclusion is directly supported
by the fact that transfersome size is nearly the same
before and after the pore passage see the inset to Fig.
.1 despite the shearing and transient bilayer ruptures
during the crossing of pores. This is only strictly true
for r rr F3–4, however, as larger transfersomesv pore
are too fragile to sustain strong shear-stress.
The same is true for the carrier-associated agents.
Some 90% of the transfersome-associated insulin, for
example, co-migrates with transfersomal carriers be-
w xfore and after the passage through a pore 19 . Simple
lipid vesicles, liposomes, either break in the pore cf.
w x.inset and Ref. 20 or else are retained at the pore
 .entrance cf. Fig. 1 .
Transfersomes are hence capable to transport
agents across the biological barriers, such as skin.
The match of the high membrane deformability and
of the good carrier sensitivity to the transepidermal
osmotic stress also maximizes the speed of carrier
w xpenetration through the skin 14 . Both permits the
epicutaneously administered transfersomal drug for-
mulations to induce a remarkable biological effect
w x21 .
At first glance, this is surprising since the highly
tortuous space between the horny-cells in the outer
skin region is sealed nearly completely by the hy-
w xdrophobic lipids 22 : the intercellular free-path width
seldom amounts to more than a few tenths of a
nanometer. Substances with a molecular weight higher
than a few hundred Dalton, consequently, do not pass
through the intact mammalian skin in significant
w xquantity 23 .
The skin permeability barrier is not uniform, how-
w xever 24,25 . We have recently shown that it contains
weak regions between the skin cells and, in particu-
lar, between the clusters of such cells. Through such
‘virtual pores’ the passage of the sufficiently potent
penetrants can be enforced A. Schatzlein and G.¨
w x.Cevc, paper in preparation and Ref. 26 . The effec-
tive diameter of an open virtual pore in the outer skin
is around 30 nm. However, it must be kept in mind
that normally only very few, if any, virtual pores in
the skin are open. Similar conclusion was also drawn
w xby others 27 , who have suggested that the maximum
pore size in the skin is around 20 nm, after the pores
were opened during the enforced trans-epidermal ma-
terial flow by means of iontophoresis.
Ultraflexible transfersomes described in this work
are the first supramolecular agent carrier that can
open and cross minute pores in the skin sponta-
w xneously 26 ; the skin protruding pathogens are their
w xnatural, evolutionary optimized kin 28 .
Transfersomes can transport their associated
drugs, including the epicutaneously applied in-
sulin, into the body spontaneously. This happens in
spite of the fact that insulin is normally prevented
from crossing the skin by its high molecular weight
of 5808 Da.
We have proven this in animals as well as in
humans. 125I-insulin transfer across the intact skin
and subsequent distribution of the insulin-derived
radioactivity in the body, is demonstrated in Fig. 3. It
is seen to closely resemble the result of an injection
of the same amount, and kind, of formulation under
the skin. While the middle panel gives the relative
amounts of radioactivity in several relevant murine
organs and in the residual body, the upper and lower
panels illustrate the corresponding whole-body distri-
bution patterns determined by means of auto-radi-
ography in rats. Owing to the lag time of the transcu-
taneous drug delivery these patterns are not identical
but sufficiently similar to support the above conclu-
sion.
The representative results of the biological experi-
ments with mice are illustrated in the top panels of
Figs. 4 and 5. The epicutaneously administered,
transfersome-associated insulin, Transfersulin cf. Fig.
.4, top: v from these data is seen to lower the blood
glucose concentration by 20–30% within 2 to 4 h. In
contrast to this, a mixture of insulin with the phos-
 .pholipidrbile-salt micelles e or a simple lipo-
 .somerinsulin blend ‘ as well as empty transfer-
 .somes not shown do not change glucose concentra-
tion in the serum significantly over the investigated
time period.
At tG4 h the effects of animal fasting and manip-
ulation in some experiments are manifest. The glu-
cose concentration in the control mice now begins to
 .vary between q10% and y20% at ts8 h . Glu-
cose in the blood of all animals treated epicuta-
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Fig. 4. The average glucose concentration change in the blood of
 . mice upper panel, in % or humans lower panel, in mg glucose
.per dl blood as a function of time after the epicutaneous
 .administration of Transfersulin at ts0 . The thick curves run
through the mean values and the thin, dashed or dotted lines
define the corresponding 95% confidence limits for uncharged
 .  .Transfersomes v , charged liposomes ‘ and mixed micelles
 .e as drug carriers, respectively. In mice, 0.45 U of insulin were
used. The dose in humans was 0.6 Urkg in all cases. Experimen-
tal and formulation details are given in the text.
neously with the non-transfersomal insulin prepara-
tion shows the same trend and is essentially indistin-
guishable from the negative controls. For example,
 .the liposomes-related data points given in Fig. 4 top
do not differ from zero significantly at tF8 h and
the results obtained with mixed micelles deviate from
zero only marginally y3.8%, P-0.1; not signifi-
.cant at P-0.05 during a similar period of time.
This suggests that simple lipid suspensions or drug
solutions do not deliver insulin across the skin. Of all
the tested insulin formulations only the drug-laden
 .transfersomes Transfersulin have this potential.
Transfersomes deposited on the skin, moreover, act
as an epicutaneous reservoir and prolong the hypo-
glycemic drug action. The surface density of the
applied drug affects the pharmacodynamics of insulin
action but does not abrogate the biological effect of
Transfersulin in the dose range 0.5–2.5 mgrcm2.
Transfersulin-induced decrease in the blood
glucose concentration builds up with time. The net
Transfersulin-induced hypoglycemia, defined as a
difference between the treated group and the negative
control, in mice typically exceeds 30% and some-
times approaches 50% of the initial blood glucose
concentration at ts8 h. This average concentration
difference between the groups treated with Transfer-
 .sulin and negative controls zero by definition is
 .highly significant P)0.001 and amounts to ap-
prox. 30% of maximum hypoglycemic activity of the
subcutaneously injected insulin at t,1 h cf. Fig. 5,
.upper right .
Comparison of area under the curve is indicative
of a high cumulative effect of the epicutaneously
applied Transfersulin. In mice, this value reaches at
least 50% of that resulting from an injection of
 .Transfersulin cf. Fig. 8, upper panel .
Fig. 5. Bottom: Characteristic suppression of blood glucose con-
centration in the normo-glycemic person after applications of
 .insulin 0.6 Urkg body weight in uncharged Transfersomes on
the intact skin. The results from the individual experiments are
shown as symbols and the corresponding mean value is given as
a curve. Top: the dose vs. action curve determined in mice left
.  .upper panel or in a human right upper panel . Lines in the upper
two panels stem from a linear-regression analysis. In the human
test person, Transfersomes of two different types were used. The
murine data pertain to cardiac blood obtained after the killing of
anesthetized mice at ts8 h after the epicutaneous insulin admin-
istration.
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Human data reveal a similar trend. Simple insulin-
 .loaded liposomes cf. Fig. 4, bottom: ‘ or the
 .corresponding mixed micelles cf. Fig. 4, top: e fail
to induce significant hypoglycemia within the time
period studied. Skin pre-treatment with a suspension
of mixed micelles and the subsequent use of standard
 .liposomes also is not efficient data not shown . Only
when insulin is applied in Transfersomes non-occlu-
sively significant systemic hypoglycemia evolves.
This happens at tG90–180 min, depending on the
detailed carrier composition. Such a delay of 45–
145 min relative to the onset of the subcutaneous
insulin action is at least partly due to the slower
w xbiological action of the carrier-associated drug 29 .
The biological effect of insulin on the skin follows
the same time-pattern and shows a similar delay in
 .humans and in the hairy animals cf. Fig. 4 . This
implies that pilosebaceous units do not act as an
important transport shunt when the drug is delivered
by means of Transfersomes.
During this study we found out that the transfer-
 .some-associated bound insulin is not readily de-
tected by the standard immuno-assays done in a
 .buffer data not shown ; insulin RIA will therefore
have to be re-validated for Transfersulin in the future.
The change in the serum insulin concentration after
 .  .Fig. 6. Glucose top and C-peptide concentration bottom in the
human blood as a function of the time after an epicutaneous
administration of 0.5 Urkg of Transfersulin based on uncharged
Transfersomes at ts0. Curves were obtained by the nearest
neighbor averaging.
Fig. 7. The change in the systemic insulinrC-peptide molar ratio
as a function of the time after epicutaneous Transfersulin admin-
istrations. Open symbols give the original data and bullets and
thick curve the averaged results; thin lines define the 90%
confidence interval. The large scattering in the original data set is
either due to the physiological day-to-day variability or to the
variations in the RIA-test performance, which could be caused
partly by the interference from Transfersomes. On several occa-
sions, the insulin level was also rather close to the detection limit
and therefore not very reliable.
the administration of up to 0.6 U of the long acting
drug per kg BW, moreover, only exceeds the detec-
w xtion limit by the factor of 4–5 30 . This makes a
reliable assessment of the systemic availability of
insulin delivered by means of Transfersomes diffi-
cult. In order to get nevertheless some relevant infor-
mation we used two procedures.
On the one hand, we tested the appearance of the
epidermally administered insulin in the murine blood
125 indirectly: we have used the I-labelled drug cf.
.Fig. 3 for this purpose. On the other hand, we also
measured the insulin and C-peptide concentration in
the blood as a function of time after the epicutaneous
insulin application. Representative result of the for-
mer tests is given in Fig. 3. The outcome of the latter
assay is illustrated in the bottom panel of Fig. 6 and
in Fig. 7.
Data given in Fig. 6 were obtained with the formu-
lation that combined intermediate and rapid drug
action. They thus simultaneously illustrate the possi-
bility to control the kinetics of Transfersulin action
and document the interdependence of serum glucose
and C-peptide, and thus insulin, concentration.
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Data given in Fig. 7 represent the results of 6
experiments done on a non-diabetic test person with
various amounts of different Transfersulin formula-
 .tions. The individual data not shown indicate that
the average insulin level remains fairly stable whereas
the corresponding C-peptide level decreases markedly
after the epicutaneous Transfersulin administration.
Despite the large experimental scattering this con-
firms that Transfersomes deliver insulin through the
intact skin. The most direct evidence for this is the
100% molar increase in the serum insulin concentra-
tion relative to the serum C-peptide level at later
times. The simultaneous blood glucose depression
also proves that the transcutaneously delivered in-
sulin is biologically active see Fig. 6 and compare
.Figs. 5 and 7 .
4. Discussion
In brief, we report the following: the highly de-
formable agent carriers prepared from the self-opti-
mizing mixtures of lipids may bring their associated
agents through the biological permeation barriers,
such as the intact skin. These novel drug carriers,
so-called Transfersomes, provide means for the non-
invasive transepidermal delivery of therapeutic agents.
When loaded with insulin and applied in a reasonable
quantity they induce therapeutically significant hypo-
glycemia in mice and in humans with a good efficacy
and reproducibility. This offers new opportunities for
the therapeutic use of large biogenic or biotechnolog-
ical agents, such as peptides, on the intact mam-
malian skin.
To date, no unanimous answer has been found to
the question of how and why could any entity as
 6 .large as typical lipid vesicle MWG10 Da cross
w xthe skin 31 . Many believe that this does not happen
at all, owing to the high permeability barrier of the
organ, which will only let molecules with a molecular
weight lower than 500 Da, at the best, pass in signifi-
w xcant quantity 23 . Other researchers would have us
believe that the epicutaneously applied vesicles disin-
tegrate in the skin and then bring their components
w xwith a poor efficacy into the body 31 . We have
previously argued that large entities can trespass the
skin if they are deformable enough to squeeze them-
selves between the skin cells through the otherwise
w xconfining pores 14 .
Data given in Fig. 1 support our original assump-
tion. They, moreover, confirm that the corresponding
activation energy, in the first approximation, can be
described within the framework of simple elasto-
mechanics. This latter conclusion is directly corrob-
orated by the linear relation between the permeability
 . and the reciprocal relative vesicle area: PA
 .2.1rr . The absence of appreciable vesicle frag-v
mentation is supported by the constancy of the aver-
age vesicle size before and after the pore passage.
Permeability results measured with liposomes con-
taining just one, relatively pure lipid phosphati-
.dylcholine represent an upper-limit estimate for the
 .value of P liposome . Two arguments speak for this.
First, the observed liposome penetration through a
pore with the diameter comparable to the vesicle size
stems largely from the liposome size poly-dispersity
 .in our case: G25% ; if a mono-disperse liposome
suspension was used and there was no overlap be-
tween the vesicle- and pore-size distributions the
actual P-value probably would be much smaller.
Second, the permeability of transfersomes with a
relatively small r rr -ratio is overestimated. Omit-v pore
ting the first measured data point from the linear
regression analysis lowers the slope in the P vs.
 .2r rr line for the transfersomes by 40%. Thepore v
˜bilayer rigidity factor, d , is proportional to this slope.
For transfersomes, this factor thus is likely to be
˜
y3smaller than that given in the text: dF5=10 .
Permeation versus pressure curve pertaining to
Transfersomes and illustrated in Fig. 2 is highly
non-linear. We think that this is due to the rapid,
˜ .stress-dependent increase in d D p . This upholds our
previous conjecture that the penetration of transfer-
somes through narrow pores is well regulated and
self-optimizing: an excessive initial deformation-
˜  .stress first decreases the value of d D p ; this, intransf
turn, reduces the deformation energy and minimizes
˜  .the stress of penetration; d D p then rises again,transf
which increases the stress, etc. For a low driving
pressure such changes are too short-lived to increase
the vesicle penetration capability appreciably. In the
range of high pressures, however, the resulting mem-
brane deformability increase persists long enough to
ensure transfersome flow through the ‘confining
pores’ at maximum speed.
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The self-regulating membrane deformability of
transfersomes is closely related to the corresponding
vesicles self-reparation capability, the latter being
essential for the transfersome stability and practical
usefulness.
To ensure the long-term colloidal stability of
vesicular suspensions, the average elastic energy of
each vesicle membrane must be higher than the ther-
mal energy: k 4RT. When this ceases to be truetransf
w xvesicles disintegrate spontaneously 32 . If membrane
elastic energy is much higher, however, the resulting
vesicles are too stiff to deform and sneak into a small
pore. k ;RT compromises nicely between thesetransf
two extremes: while it makes the membrane fluctua-
 .tions probable cf. inset to Fig. 2 it also maintains
 .vesicle stability cf. inset to Fig. 1 .
In spite of this, the local elastic energy of a
transfersome membrane may transiently get lower
than RT. This happens, for example, when the vesi-
cle rigidity factor is temporarily lowered at some
“ “
˜ .  .strongly deformed site, k r sk d r <RTtransf transf
˜ld<1, due to the stress-induced vesicle mem-
brane adaptation. The non-linear pressure-dependence
of transfersome passage through a micro-porous
 .membrane cf. Fig. 2 illustrates this functional de-
pendence: for the low applied pressures the barrier
permeability to the transfersome suspension is typi-
cally )104 lower than for the pure water. At high
pressures, the situation changes: the trans-pore flow
of transfersomes now resembles that of water, 1000
times smaller.
High suspension-driving pressures nearly com-
pletely eliminate the effects of carrier- and pore-size
mismatch. This is certainly true for the transfersomes
with a diameter that does not exceed the pore size by
more than the factor of 3.
Transcutaneous short-cuts, such as glands or hair-
follicles, are known to play an important role in the
w xprocess of molecular diffusion across the skin 23 . In
spite of this, such shunts are either too sparse or too
impermeable to let a large molecule, such as insulin,
through the skin in appreciable quantity. This ex-
plains why an epicutaneous application of insulin in
 .the mixed-lipid micelles or liposomes cf. Fig. 4 has
no significant hypoglycemic effect.
Shunts are also not crucial for the passage of
transfersomes through the skin. If they were impor-
tant, the biological action of the corresponding
transepidermal drug administration on various ani-
mals or humans should differ considerably. This
would manifest itself, in particular, in the variable
onset of the insulin-dependent hypoglycemic action.
 . Our experiments with mice cf. Fig. 4 , rats cf. Fig.
.  .  .3 , pigs not illustrated and humans cf. Figs. 4–6
exclude such a possibility. Indeed, to date, we were
unable to detect any major pharmacodynamic differ-
ence between the various test species mice, nude
.mice, rats, rat tails, pigs, humans in spite of the fact
that mice have at least 10-times higher hair-follicle
density than pigs or humans.
Material transport into the skin could involve vesi-
cle penetration through the cutaneous micro-lesions.
This is unlikely to have played a role in our own
experiments. If the skin was damaged and anoma-
lously permeable to the insulin molecules, the corre-
sponding transport increase should show-up in all
tested formulations, but we only detected high trans-
fer rates with transfersomes. The effects of skin
lesions, if they did exist, moreover, should be mir-
rored in the increased inter-individual variability and
the dependence of the experimental data-scattering on
the mode of drug administration. In fact, the average
standard deviations after subcutaneous injections and
epicutaneous administrations are nearly the same,
18% and between 13% and 24%, respectively, for the
single person data.
The last unpleasant possibility would be that our
formulations were affecting the skin barrier directly.
Bile salts, for example, are known to affect the
w xpermeability barrier of nasal mucosa 9,33 . Have
such salts in our formulations also partly fluidized the
skin and thus mediated a hypoglycemic insulin ac-
tion?
If this were case, the measured decrease in the
blood glucose concentration would have to increase,
or at least remain constant, with increasing bile salt
concentration. We observed just the opposite: the
epicutaneously applied insulinrmixed micelles mix-
tures, which contain the highest bile salt concentra-
tion of all formulations studied, had no significant
 .hypoglycemic effect cf. Figs. 2 and 4 .
We thus conclude that the reported hypoglycemic
effect of Transfersulin is genuine. It is neither medi-
ated by the skin-fluidization nor by the presence of
skin lesions or merely the use of particulate carriers.
Indeed, none of these factors seems to have played a
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role in our experiments; the lack of hypoglycemic
effect in mice treated with empty carriers, with an
insulin solution or with the non-transfersomal insulin
suspensions on the skin supports this conclusion. We
infer that simple liposomes are insufficiently de-
formable to get across the skin and argue that mi-
celles are too small to sense a strong enough transepi-
dermal osmotic gradient to be driven across the skin.
The hypoglycemia measured after the non-invasive
Transfersulin application, consequently, must be the
result of transfersome-mediated drug transport across
the skin. Our studies with the radioactive insulin
w x .support such conclusion 19 and Fig. 3 ; so does the
similar temporal dependence of C-peptide and glu-
 .cose levels in the blood cf. Fig. 6 .
C-peptide is a side product of insulin bio-synthe-
sis. If the measured hypoglycemia was not due to an
epicutaneous Transfersulin action, but rather a re-
sponse to the action of endogenic insulin, the serum
C-peptide concentration in the blood should increase
in parallel with decreasing blood glucose concentra-
tion. This should be true for the blood sugar concen-
trations higher than ;60 mgrdl at least. Our result
show precisely the opposite trend, however. The
similarity of time-profiles for the measured blood
 .glucose cf. Fig. 6, top and C-peptide concentrations
 .cf. Fig. 6, bottom thus provides a compelling evi-
dence for the biological action of the exogenous,
epicutaneously administered insulin in Transfer-
somes.
The lowest point in the systemic hypoglycemia
measured after an epicutaneous Transfersulin applica-
tion normally exceeds 25% and often reaches 45"
10% of the result generated by the corresponding
 .subcutaneous Transfersulin injection not shown .
This only gives a lower-limit estimate for the total
efficacy of the epidermally applied Transfersulin,
however. Data shown in Fig. 8 reveal that the Trans-
fersulin-mediated hypoglycemia actually persist much
longer than that induced by a subcutaneous injection
w xof Transfersulin 29 . Integration of individual hypo-
glycemia vs time curves suggests that the bio-avail-
ability of Transfersulin on the skin typically reaches
 .75% cf. Fig. 8 and sometimes approaches 100% of
w xthe action of insulin under the skin 29 .
Our results with Transfersulin thus supersede those
of other previous non-invasive insulin applications.
Even the best corresponding previous attempt, such
Fig. 8. Cumulative effect of the subcutaneously injected Actrapid
 .‘Rapid insulin’, thin curves or of the corresponding amount of
 .Transfersulin administered on the skin thick curves in mice
 .  .upper panel or a human lower panel . The results with human
Transfersulin were obtained by calculating the area under the
w xcurve given in the bottom panel of Fig. 3 in Ref. 37 ; curve
labelled as ‘Rapid insulin’ in mice was obtained by the proper
 .3-fold scaling of the data obtained after an injection of 0.15 U
.s.c., since the injection of 0.45 Actrapid in mice is lethal.
w xas the use of iontophoresis 34 or trans-nasal spray
w x11,35 , only brought less than 5% and less than 20%
of insulin molecules, respectively, into the systemic
blood circulation. The intra-pulmonal insulin admin-
istrations appears to be more efficient up to 50%,
w x33,36 but is likely to be burdened by the poor
administration reproducibility and also only gives rise
 .to a short 2–4 h hypoglycemia.
The improvement over previous achievements calls
for caution. Could it be that the blood glucose con-
centration in our experiments on human was changed
by fasting? It stands to reason that this was not the
case. If it was, the measured hypoglycemia should
not be proportional to the drug amount used; the
blood glucose level should never increase toward the
end of experiments; the efficacy of each given prepa-
ration should be independent of carrier character-
istics, etc. None of these implications is true, how-
 .ever cf. Figs. 4–6 .
Penetration of all properly made transfersomes is
sufficiently controllable to ensure the insulin-induced
hypoglycemia in mice and humans to be proportional
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to the applied agent amount in the dose range below
0.2 U Transfersulin s.c.ranimal and below 0.6 U
Transfersulin e.c.ranimal cf. upper two panels in
.Fig. 5 . In the normo-glycemic humans, dose linear-
ity is observed below approx. 0.6 U Transfersulin
 .e.c.rkg see the upper part of Fig. 5 . The corre-
 .sponding linear-regression analyses straight lines
 .give correlation coefficients of Rs0.96 B and
 .Rs0.86 v for mice and Rs0.94 for man and
confirm that the observed effects are due to the
non-invasively applied Transfersulin rather than to
some other drug- or carrier-independent effect. The
averaged results of measurements with humans be-
fore and after the onset of hypoglycemic area signifi-
cant at the level of P-0.001.
Transfersulin, in our experience, is reasonably effi-
cient. In our experiments to date, the application area
was varied between 20 and several hundred cm2. It
may be expected that, finally, Transfersulin will be
administered over an area of merely 40 cm2 or less to
deliver the basal daily supply of insulin to a typical
type I diabetes patient.
Hope is further nourished by the results of re-
peated experiments on one individual cf. Fig. 5,
.bottom with the optimized Transfersulin formulation
which are clearly superior to our earlier data on a
w xdifferent test person 13 . The robustness of new
results, together with the linearity of the dose vs.
action curve, suggests that Transfersulin has, indeed,
the potential to become a therapeutic formulation,
provided that the batch to batch and the inter-patients
variability can be made, or will turn out to be, small
enough.
This demonstrates that it is possible to draw thera-
peutic benefits from the basic studies of elasto-mech-
anic properties of lipid vesicles and from the rational
design of new quasi-biological materials.
Acknowledgements
This study was supported in part by the Deutsche
Forschungsgemeinschaft through the research grant
.Ce 9r1 . We are thankful to the Central Animal
Facilities of Gesellschaft fur Strahlenforschung¨
 .Neu-Herberg b. M. , in particular to Dr. Griebel and
Mrs. Mollenstadt for their generous hospitality. Tech-¨ ¨
nical assistance of Karin Putz in the experiments with
mice is highly appreciated.
References
w x1 M. Buysschaert, Optimized insulin delivery: achievements
 .and limitations, Diabete Metabol. 15 1989 188–203.
w x2 V. Lassmann-Vague, Unusual ways for administration of
 .insulin, Diabete Metabol. 14 1989 728–731.
w x3 M. Saffran, G.K. Sudesh, C. Savariar, J.C. Burnham, F.
 .Williams, D.C. Neckers, Science 233 1986 1081–1084.
w x4 N. Das, M.K. Basu, M.K. Das, Oral application of insulin
 .encapsulated liposomes, Biochem. Int. 16 1988 983–989.
w x w x5 Y.W. Cho, M. Flynn, Oral delivery of insulin letter , Lancet
 .23-30 1989 1518–1519.
w x6 R.K. Liedtke, K. Suwelack, K. Karzel, Wirkung peroraler
und transdermaler Insulin-Praparationen auf die Blut-
glukose-Konzentration bei Mausen, Arzneim.-Forsch. Drug
 .Res. 40 1990 880–883.
w x7 P.Y. Wang, Implantable reservoir for supplemental insulin
delivery on demand by external compression, Biomaterials
 .10 1989 197–201.
w x8 H. Walter, A. Gunther, D. Kronski, I. Flaschentrager, H.
Mehnert, Implantation of programmable infusion pumps for
insulin delivery in type I diabetic patients, Klin. Wochen-
 .schr. 67 1989 583–587.
w x9 B.J. Aungst, N.J. Rogers, E. Shefter, Comparison of nasal,
rectal, buccal, sublingual and intramuscular insulin efficacy
and the effects of a bile salt absorption promoter, J. Pharma-
 .col. Exp. Ther. 244 1988 23–27.
w x10 G.C.Y. Chiou, C.Y. Chuang, M.A. Chang, Systemic deliv-
ery of insulin through eyes to lower the glucose concentra-
 .tion, J. Ocul. Pharmacol. 5 1989 81–91.
w x11 M. Mishima, S. Okada, Y. Wakita, M. Nakano, Promotion
of nasal absorption of insulin by glycyrrhetinic acid deriva-
 .tives, I. J. Pharmacobio.-Dynam. 12 1989 31–36.
w x12 G. Cevc, Lipid properties as a basis for the modelling and
 .design of liposome membranes, in: G. Gregoriadis Ed. ,
Liposome Technology, 2nd ed., CRC-Press, Boca Raton,
FL, 1992, pp. 1–36.
w x13 G. Cevc, Material transport across permeability barriers by
 .means of lipid vesicles, in: R. Lipowsky Ed. , Handbook of
Physics of Biological Systems, vol. I, Elsevier Science,
Chap. 9, 1995, pp. 441–466.
w x14 G. Cevc, G. Blume, Lipid vesicles penetrate into intact skin
owing to the transdermal osmotic gradients and hydration
 .force, Biochim. Biophys. Acta 1104 1992 226–232.
w x15 G. Gompper, D.M. Kroll, Driven transport of fluid vesicles
 .through narrow pores, Phys. Rev. E 52 1995 4198–4208.
w x16 W. Helfrich, Elastic properties of lipid bilayers Theory and
 .possible experiments, Z. Naturforsch 28 1973 693–703.
w x17 S. Leibler, Curvature instability in membranes, J. Physique
 .  .France 47 1986 507–516.
w x18 D. Needham, E. Evans, Structure and mechanical properties
 .of giant lipid DMPC vesicle bilayers from 20 Celsius
( )G. Ce˝c et al.rBiochimica et Biophysica Acta 1368 1998 201–215 215
below to 10 Celsius above the liquid - crystaline phase
 .transition at 24 degree Celsius, Biochemistry 27 1988
8261–8269.
w x19 G. Cevc, G. Schatzlein, D. Gebauer, G. Blume, Ultra-high¨
efficiency of drug and peptide transfer through the intact
skin by means of novel drug carriers, transfersomes, in:
 .K.R. Brain, V.J. James, K.A. Walters, Eds. , Prediction of
Percutaneous Penetration, 3rd International Conference, 14–
16 April, 1993, Vol. 3b, STS Publishing, Cardiff, pp. 226–
236.
w x20 L.D. Mayer, M.J. Hope, P.R. Cullis, Vesicles of variable
sizes produced by a rapid extrusion procedure, Biochim.
 .Biophys. Acta 856 1986 161–168.
w x21 P. Gonzalez, M.E. Planas, L. Rodriguez, S. Sanchez, G.
Cevc, Noninvasive, percutaneous induction of topical anal-
gesia by a new type of drug carriers and prolongation of the
local pain-insensitivity by analgesic liposomes, Anesth.
 .Analg. 75 1992 615–621.
w x  .22 J. Hadgraft, R.H. Guy Eds. , Transdermal Drug Delivery,
Developmental Issues and Research Initiatives, Marcel
Dekker, New York, 1989.
w x23 R.O. Potts, R.H. Guy, Prediciting skin permeability, Pharm.
 .Res. 9 1992 663–669.
w x24 M. Fartasch, I.D. Bassukas, T.L. Diepgen, Structural rela-
tionship between epidermal lipid lamellae, lammelar bodies
and desmosomes in human epidermis, an ultrastructural
 .study, Br. J. Dermatol. 128 1993 1–9.
w x25 E. Christophers, M. Schubert, C. Goos, The epidermis, in:
 .M.W. Greaves, S. Shuster Eds. , Pharmacology of the Skin,
Vol. 1, Springer, Berlin, 1989, pp. 3–30.
w x26 A. Schatzlein, G. Cevc, Skin penetration by phospholipid¨
vesicles, transfersomes, as visualized by means of the confo-
cal laser scanning microscopy, in: G. Cevc, F. Paltauf
 .Eds. , Phospholipids, Characterization, Metabolism and
Novel Biological Applications, AOCS Press, 1995, pp. 191–
209.
w x27 V. Aguiella, K. Kontturi, L. Murtomaki, P. Ramırez, Esti-¨ ´
mation of the pore size and charge density in human cadaver
 .skin, J. Control. Release 32 1994 249–257.
w x28 A. Paul, G. Cevc, B.K. Bachhawat, Transdermal immuniza-
tion with large proteins by means of ultradeformable drug
 .carriers, Eur. J. Immunol. 25 1995 35221–35224.
w x  .29 G. Cevc, Dermal insulin, in: M. Berger, F.A. Gries Eds. ,
Frontiers in Insulin Pharmacology, Georg Thieme Verlag,
Stuttgart, 1993, pp. 161–169.
w x30 A.A. Starke, L. Heinemann, A. Hohmann, M. Berger, The
action profiles of human NPH insulin preparations, Diabetic
 .Med. 6 1989 239–244.
w x31 H. Schreier, J. Bouwstra, Liposomes and niosomes as topi-
cal drug carriers, dermal and transdermal drug delivery, J.
 .Control. Release 30 1994 1–15.
w x  .32 R. Lipowsky, Vesicle thermodynamics, Nature 349 1991
475–481.
w x33 D.T. O’Hagan, L. Illum, Absorption of peptides and pro-
teins from the respiratory tract and the potential for develop-
ment of locally administered vaccine, Crit. Rev. Ther. Drug
 .Carrier Syst. 7 1990 35–97.
w x34 B.R. Meyer, H.L. Katzeff, J. Eschbach, J. Trimmer, S.R.
Zacharias, S. Rosen, D. Sibalis, Transdermal delivery of
human insulin to albino rabbits using electrical current, Am.
 .J. Med. Sci. 297 1989 321–325.
w x35 R. Kimmerle, G. Friffing, A. McCall, N.B. Ruderman, E.
Stoltz, J.C. Melby, Could intranasal insulin be useful in the
treatment of non-insulin dependent diabetes mellitus?, Dia-
 .betes Res. Clin. Pract. 13 1991 69–76.
w x36 L.L. Wearley, Recent progress in protein and peptide deliv-
ery by noninvasive routes, Crit. Rev. Ther. Drug Carrier
 .Syst. 8 1991 331–394.
w x37 G. Cevc, A. Schatzlein, G. Blume, Transdermal drug carri-¨
ers, basic properties, optimization and transfer-efficiency in
the case of epicutaneously applied peptides, J. Control.
 .Release 36 1995 3–16.
w x38 G. Cevc, 1991, Eur. pat. 91 114 163.8-2114.
